Jay on for Craig Hottenbach's questions to GoodRx Holdings Inc (GDRX) leadership • Q2 2025
Question
Jay, on behalf of Craig Hottenbach at Morgan Stanley, asked for details on the cost controls and margin levers being used to maintain EBITDA guidance despite lower revenue, and also inquired about any shifts in consumer prescription fill behavior.
Answer
CFO Chris McGinnis explained that margins are being maintained through a combination of favorable mix shift (as lost ISP volume was lower margin) and disciplined cost controls, including a workforce reduction and resource reallocation. CEO Wendy Barnes reiterated this was a deliberate move to align the organization with key strategies. McGinnis noted that consumer behavior has likely shifted short-term to funded benefits due to higher cash prices, but he anticipates tailwinds will reverse this trend.